Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EPANOVA vs AMINOSYN 10%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Omega-3 fatty acids (EPA and DHA) reduce hepatic very low-density lipoprotein (VLDL) synthesis and increase triglyceride clearance from circulating VLDL particles through activation of lipoprotein lipase.
Aminosyn 10% provides a mixture of essential and non-essential amino acids to support protein synthesis and maintain nitrogen balance in patients unable to tolerate adequate oral or enteral nutrition. Each amino acid serves as a substrate for protein synthesis, hormone production, and other metabolic processes.
As an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia (≥500 mg/d L)
Parenteral nutrition for patients with inadequate oral or enteral intake,Prevention of nitrogen loss in catabolic states,Treatment of negative nitrogen balance
4 g orally once daily as 4 capsules of 1 g each with food.
Intravenous infusion: 1-1.5 g/kg/day (as amino acids), typically 500 m L of 10% solution (50 g amino acids) over 8-12 hours daily.
Terminal elimination half-life approximately 89 hours (range 59–144 hr); allows weekly intramuscular dosing.
Amino acids: 0.5-1 hour for free amino acids; terminal half-life of infused nitrogen is approximately 2-4 hours; clinical context: reflects rapid uptake and metabolism.
Epanova (omega-3-carboxylic acids) is hydrolyzed by pancreatic lipase; free fatty acids are absorbed and then metabolized via beta-oxidation similarly to dietary fatty acids.
Amino acids are metabolized primarily in the liver via deamination, transamination, and other pathways. The carbon skeletons enter the citric acid cycle or gluconeogenesis, and nitrogen is converted to urea.
Primarily hepatic metabolism via omega-oxidation and subsequent conjugation; renal excretion of metabolites: ~15% unchanged in urine; biliary/fecal elimination accounts for ~85% as metabolites.
Renal (primarily as amino acids and metabolites); ~90% of infused amino nitrogen is excreted renally within 24-48 hours; <5% biliary/fecal.
Highly protein bound (>99%), primarily to albumin and to a lesser extent to alpha-1-acid glycoprotein.
Amino acids: negligible protein binding (<5%); albumin binds some tryptophan and branched-chain amino acids minimally.
Volume of distribution approximately 0.2 L/kg, indicating limited extravascular distribution.
Amino acids: 0.3-0.5 L/kg (approximates extracellular fluid volume); clinical meaning: distributes primarily in ECF.
Intramuscular: ~100% (absolute bioavailability not determined in humans due to lack of IV formulation; presumed complete absorption from IM site).
Intravenous: 100% (only route of administration); not absorbed orally as parenteral formulation.
No dose adjustment required for renal impairment, including end-stage renal disease on dialysis.
GFR <50 m L/min: reduce dose to 0.5-0.8 g/kg/day. GFR <15 m L/min: avoid or use with extreme caution, monitor serum amino acids.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not recommended for severe hepatic impairment (Child-Pugh C) due to lack of data.
Child-Pugh class B: reduce dose by 50%. Child-Pugh class C: contraindicated due to risk of hepatic encephalopathy.
Safety and efficacy not established in pediatric patients under 18 years; no recommended dosing.
Neonates: 2-3 g/kg/day IV. Infants/children: 1.5-2.5 g/kg/day IV. Adjust based on metabolic status and growth.
No specific dose adjustment recommended; use with caution due to increased risk of adverse effects and comorbidities. Monitor hepatic function closely.
Initiate at low end of adult dose (1 g/kg/day IV), monitor renal function and adjust accordingly; consider reduced metabolic clearance.
None
None
May increase LDL-C levels; monitor LDL-C during therapy.,May prolong bleeding time; use with caution in patients receiving anticoagulants or with bleeding disorders.,Risk of atrial fibrillation or flutter in patients with prior cardiovascular disease or diabetes; discontinue if symptoms occur.
Risk of hyperammonemia, especially in patients with hepatic impairment or inborn errors of urea cycle,Electrolyte imbalances may occur; monitor serum electrolytes frequently,Monitor for signs of infection at infusion site,Use caution in patients with renal impairment, as accumulation of amino acids may occur,May cause metabolic acidosis in certain patients
Hypersensitivity to Epanova or any of its components.
Hypersensitivity to any component,Inborn errors of amino acid metabolism (e.g., maple syrup urine disease, phenylketonuria),Severe hepatic failure with hyperammonemia,Severe renal failure without dialysis support,Patients with uncorrected electrolyte imbalances
Epanova may be taken with or without food, but taking with a low-fat meal may improve absorption. Avoid high-fat meals as they can increase GI side effects. Grapefruit juice has no known interaction. No significant food restrictions; maintain a heart-healthy diet.
No direct food interactions, but ensure adequate non-protein calorie intake (carbohydrates, fats) to prevent amino acid utilization for energy. Avoid concurrent use with high-protein oral diets without medical supervision. For patients with phenylketonuria (PKU), verify product composition as some contain phenylalanine.
Pregnancy Category C. In animal reproduction studies, oral administration of icosapent ethyl to pregnant rats and rabbits during organogenesis at doses up to 5 and 7 times the human dose (based on body surface area) did not reveal evidence of harm to the fetus. However, there are no adequate and well-controlled studies in pregnant women. Fetal risk cannot be ruled out; use only if potential benefit justifies potential risk.
Aminosyn 10% is an amino acid solution used for parenteral nutrition. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted with this formulation. In the first trimester, the risk of teratogenicity is theoretical; essential amino acids are necessary for fetal development, but excesses or imbalances may be harmful. During the second and third trimesters, supplementation may be beneficial for maternal and fetal nutrition, but potential risks include metabolic acidosis or electrolyte disturbances if not properly monitored.
Excretion into human milk unknown. M/P ratio not available. Caution should be exercised when administered to a nursing mother. Because many drugs are excreted in human milk, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Aminosyn 10% is not excreted into breast milk in significant amounts; its components are endogenous substances. The M/P ratio is not applicable as it is not a drug with active transport. Maternal use during breastfeeding is considered safe if the infusion is necessary for maternal health. No adverse effects on the nursing infant are expected.
No specific dosing adjustments are recommended during pregnancy based on pharmacokinetic changes. The pharmacokinetics of icosapent ethyl have not been studied in pregnant women. Dose should be individualized based on triglyceride levels and tolerability.
Pregnancy increases plasma volume and glomerular filtration rate, potentially altering amino acid clearance. However, no specific dose adjustments are established for Aminosyn 10%. Dosage should be individualized based on nitrogen balance, weight gain, and metabolic parameters. Close monitoring of amino acid levels and metabolic status is recommended to avoid toxicities or deficiencies.
For patients with severe hypertriglyceridemia (≥500 mg/d L), Epanova (omega-3 carboxylic acids) reduces triglyceride levels by approximately 25-45% at doses of 2-4 g/day. Absorption is enhanced when taken with a low-fat meal; however, if meals cause GI distress, taking with food is still recommended. Avoid use in patients with known fish allergy. Monitor for atrial fibrillation or flutter, especially in elderly patients or those with cardiovascular risk factors. Dose should be adjusted for renal impairment (e GFR <30 m L/min).
Use central line administration for concentrations >5% to reduce thrombophlebitis risk. Monitor serum electrolytes, BUN, glucose, and liver function tests frequently. Adjust infusion rate based on metabolic tolerance; start at 100 m L/hr and increase gradually. Contraindicated in severe hepatic disease, uremia, or maple syrup urine disease. Do not use as a sole source of nutrition; provide concurrent calories from carbohydrates and fats.
Take Epanova exactly as prescribed, typically 2-4 capsules once daily with food to reduce GI side effects.,Do not break, crush, or chew the capsules; swallow them whole.,Continue a low-fat diet and exercise program while on this medication.,Inform your doctor if you experience symptoms of an allergic reaction (rash, itching, swelling, severe dizziness, trouble breathing).,Report any irregular heartbeat, chest pain, or shortness of breath immediately.,This medication may increase bleeding risk; tell your doctor if you have a bleeding disorder or take blood thinners (e.g., warfarin).,Store at room temperature away from moisture and heat.
This solution provides amino acids for protein building when you cannot eat normally.,Report signs of infection at catheter site: redness, swelling, pain, or drainage.,Common side effects include nausea, flushing, and warmth during infusion.,You will need regular blood tests to monitor kidney, liver, and metabolic function.,Inform your doctor if you have diabetes, kidney disease, or a history of gout.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EPANOVA vs AMINOSYN 10%, answered by our medical review team.
EPANOVA is a Parenteral Nutrition Solution that works by Omega-3 fatty acids (EPA and DHA) reduce hepatic very low-density lipoprotein (VLDL) synthesis and increase triglyceride clearance from circulating VLDL particles through activation of lipoprotein lipase.. AMINOSYN 10% is a Parenteral Nutrition Solution that works by Aminosyn 10% provides a mixture of essential and non-essential amino acids to support protein synthesis and maintain nitrogen balance in patients unable to tolerate adequate oral or enteral nutrition. Each amino acid serves as a substrate for protein synthesis, hormone production, and other metabolic processes.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EPANOVA and AMINOSYN 10% depend on the specific clinical indication. These are both Parenteral Nutrition Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EPANOVA is: 4 g orally once daily as 4 capsules of 1 g each with food.. The standard adult dose of AMINOSYN 10% is: Intravenous infusion: 1-1.5 g/kg/day (as amino acids), typically 500 m L of 10% solution (50 g amino acids) over 8-12 hours daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EPANOVA and AMINOSYN 10% in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EPANOVA is classified as Category C. Pregnancy Category C. In animal reproduction studies, oral administration of icosapent ethyl to pregnant rats and rabbits during organogenesis at doses up to 5 and 7 times the huma. AMINOSYN 10% is classified as Category C. Aminosyn 10% is an amino acid solution used for parenteral nutrition. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.